Katie Adams –
Wednesday, October 21st, 2020
The news comes 6 weeks after an individual in AstraZenecas U.K. trial developed transverse myelitis, a neurological condition in which the spinal cord becomes inflamed. The drugmaker resumed the trial in the U.K. Sept. 12 after getting approval from the Medicines Health Regulatory Authority, the countrys equivalent of the FDA, however has yet to continue the trial in the U.S
The University of Oxford, which is jointly establishing the vaccine with AstraZeneca, told CNBC the participants death did not reveal any concerns about the trials security.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.
A participant in AstraZenecas Brazil COVID-19 vaccine trial who died did not get the vaccine, a confidential source familiar with the matter informed Bloomberg.
. More short articles on pharmacy: Kodak says it will make APIs despite insider-trading allegationsFDA advisory panel to openly discuss COVID-19 vaccine approval processHealth policy experts prompt US to launch all COVID-19 vaccine clinical trial procedures
” The independent review in addition to the Brazilian regulator have actually recommended that the trial should continue,” University of Oxford spokesperson Alexander Buxton told CNBC.